Funding for this research was provided by:
Canadian Institutes of Health Research (299962, Post-Doc Fellowship)
Natural Sciences and Engineering Research Council of Canada (CGS D)
Text and Data Mining valid from 2019-03-27
Received: 21 November 2018
Accepted: 11 March 2019
First Online: 27 March 2019
Ethics approval and consent to participate
: This article pools data from previously published studies as well as previously unpublished data. All studies were approved by the Université de Sherbrooke human ethics committee and participants provided informed consent. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Not applicable.
: MAR is supported by a scholarship from the Natural Sciences and Engineering Research Council of Canada (CGS D). DPB is a recipient of a Canadian Institutes of Health Research Post-doctoral fellowship. ACC holds the GSK Chair in Diabetes of the Université de Sherbrooke that has been created in part through a donation of $1 million by GSK to the Université de Sherbrooke. ACC holds research funding from the Canadian Institutes of Health Research, Canadian Diabetes Association, Fonds de recherche Québec – Santé, GSK, Janssen, Merck, Pfizer, AstraZeneca, Aventis, NovoNordisk, Eli Lilly, UniQure, Caprion Biosciences. ACC has participated in advisory boards/meetings for the companies UniQure, Merck, Janssen, Novartis, NovoNordisk and AstraZeneca. DPB, ML, and ACC are members of the Fonds de recherche du Québec – Santé funded Centre de recherche du Centre hospitalier universitaire de Sherbrooke.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.